How I treat adult T-cell leukemia/lymphoma.

Blood

Department of Medicine, Weill Cornell Medical College, New York, NY.

Published: January 2021

Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive T-cell malignancy that arises in a proportion of individuals who are long-term carriers of human T-lymphotropic virus type 1. The median survival of aggressive subtypes is 8 to 10 months; with chemotherapy-based approaches, overall survival has remained largely unchanged in the ∼35 years since ATL was first described. Through the use of 4 representative case studies, we highlight advances in the biological understanding of ATL and the use of novel therapies such as mogamulizumab, as well as how they are best applied to different subtypes of ATL. We discuss the implementation of molecular methods that may guide diagnosis or treatment, although we accept that these are not universally available. In particular, we acknowledge discrepancies in treatment between different countries, reflecting current drug licensing and the difficulties in making treatment decisions in a rare disease, with limited high-quality clinical trial data.

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019004045DOI Listing

Publication Analysis

Top Keywords

adult t-cell
8
t-cell leukemia/lymphoma
8
treat adult
4
leukemia/lymphoma adult
4
atl
4
leukemia/lymphoma atl
4
atl highly
4
highly aggressive
4
aggressive t-cell
4
t-cell malignancy
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!